文献速递类风湿关节炎系统性红斑狼疮血管炎

利妥昔单抗治疗风湿病中严重感染预测与低丙种球蛋白血症影响

Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases.
PubMed 文献 · Arthritis Rheumatol · 2019-09-26

该回顾性纵向研究纳入700例接受利妥昔单抗(RTX)治疗的风湿与肌肉骨骼疾病(RMD)患者,评估严重感染事件(SIE)预测因素及低丙种球蛋白血症对SIE率、体液免疫应答和持久性的影响。结果显示SIE率为9.8/100人年,低IgG(<6 g/L)在基线和治疗期间均为一致预测因素,且低IgG患者SIE率更高。建议基线和每周期前监测免疫球蛋白水平以识别高风险患者。

要点

  • 低IgG(<6 g/L)在基线和治疗期间均与SIE风险升高相关。
  • 既往SIE史、癌症、慢性肺病、糖尿病、心衰及高皮质类固醇剂量也预测SIE。
  • RTX相关中性粒细胞减少、较高IgM和较长再治疗间隔亦为SIE预测因素。

核心结论

  • 低IgG是RTX治疗期间SIE的持续预测因素,应在基线和每周期前监测免疫球蛋白水平以识别高风险患者。
  • 对低IgG患者应进行个体化风险获益评估,因RTX更换为其他治疗时感染谱可能增加。

研究设计与样本

  • 单中心回顾性纵向研究,纳入700例接受RTX治疗的风湿与肌肉骨骼疾病患者。
  • 在基线和每个治疗周期后4-6个月测量免疫球蛋白水平;采用多变量logistic回归评估SIE基线预测因素,对第2-4个RTX周期使用混合效应logistic回归模型。

主要发现

  • 共记录281例次SIE,发生于176例患者,总SIE率为9.8/100人年。
  • 110例低IgG患者中,基线低IgG者SIE率为16.4/100人年,治疗期间或之后获得低IgG者为21.3/100人年,而IgG正常者为9.7/100人年。
  • 8例接受疫苗挑战的患者中5例(63%)对肺炎球菌和流感嗜血杆菌的体液应答受损;11例换用其他生物改善病情抗风湿药的患者中仅4例(36%)IgG恢复正常。

关键数值与推荐

  • SIE预测因素包括非RTX特异性合并症(既往SIE史、癌症、慢性肺病、糖尿病、心衰)、较高皮质类固醇剂量及RTX特异性因素(基线和治疗期间低IgG<6 g/L、RTX相关中性粒细胞减少、较高IgM、较长再治疗间隔),但非B细胞计数或耗竭状态。

临床怎么用

  • 建议在基线和每个RTX周期前监测免疫球蛋白水平,以识别SIE高风险患者。
  • 对低IgG患者应进行个体化风险获益评估,并注意RTX更换为其他治疗时感染风险可能增加。

局限性

  • 单中心回顾性研究设计可能限制结果的普遍性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate predictors of serious infection events (SIEs) during rituximab (RTX) therapy and effects of hypogammaglobulinemia on SIE rates, and humoral response and its persistence after discontinuation of RTX in the treatment of rheumatic and musculoskeletal diseases (RMDs). METHODS: A retrospective longitudinal study of 700 RMD patients treated with RTX in a single center was conducted. Immunoglobulin levels were measured at baseline and at 4-6 months after each treatment cycle. Baseline predictors of SIEs were assessed using multivariable logistic regression; for RTX cycles 2-4, a mixed-effects logistic regression model was used. RESULTS: A total of 507 patients (72%) had rheumatoid arthritis, 94 (13%) had systemic lupus erythematosus, 49 (7%) had antineutrophil cytoplasmic antibody-associated vasculitis, and 50 (7%) had other RMDs. The number of SIEs recorded was 281 in 176 patients (9.8 per 100 person-years). Predictors of SIEs included non-RTX-specific comorbidities (previous history of SIE, cancer, chronic lung disease, diabetes mellitus, and heart failure), higher corticosteroid dose, and RTX-specific factors, including low IgG (<6 gm/liter) both at baseline and during treatment, RTX-associated neutropenia, higher IgM, and longer time to RTX re-treatment, but not B cell count or depletion status. Of 110 patients with low IgG, SIE rates were higher in those with low IgG at baseline (16.4 per 100 person-years) and in those who acquired low IgG during or after RTX treatment (21.3 per 100 person-years) versus those with normal IgG (9.7 per 100 person-years). Five of 8 patients (63%) had impaired humoral response to pneumococcus and hemophilus following vaccination challenge, and only 4 of 11 patients (36%) had IgG normalized after switching biologic disease-modifying antirheumatic drugs. CONCLUSION: Immunoglobulin levels should be monitored at baseline and before each RTX cycle to identify patients at risk of SIEs. Individualized risk-benefit assessment should be undertaken in those with lower IgG as this is a consistent SIE predictor and may increase infection profiles when RTX is switched to different therapies.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Md Yusof MY, Vital EM, McElvenny DM, et al. Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases. Arthritis Rheumatol. 2019. PMID: 31131994. doi:10.1002/art.40937

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。